Marc Straus

Last updated

Marc Straus
Dr Marc Straus.jpg
Born
Marc Joshua Straus

New York City
Nationality American
Alma materBA – Franklin & Marshall College, MD – SUNY Downstate Medical Center
Occupation(s)Art collector and Gallery Owner, Oncologist, poet
SpouseLivia Straus

Marc Straus is an American oncologist, art collector, poet, and writer. [1] He is the author of more than 40 scientific papers on the treatment of various types of cancer. Straus was among the first oncologists to introduce the use of continuous infusion for the delivery of chemotherapy, a practice that has since become standard. [2]

Contents

Straus is the founder of Hudson Valley MOCA and the Marc Straus Gallery in New York City.

Early life and education

Straus was raised in Long Island and in Brooklyn. [1] His father was an orphaned immigrant who came to the United States at age 15 and later owned a textile business on Manhattan’s Lower East Side. Growing up, Straus worked in the shop on Sundays. [3]

Straus received a B.A. degree from Franklin & Marshall College in 1964 and an M.D. from State University of New York Downstate Medical Center in 1968. He interned at Kings County Hospital in Brooklyn in 1968–69. [4]

From 1969 to 1971, Straus was a staff associate at the National Cancer Institute. He was a resident a Barnes Hospital in St. Louis from 1971–72. [4]

Medical career

Straus served as SesenioCacancer rcer Research internist at the National Cancer Institute Veteran’s Administration (NCI-VA) Medical Oncology Branch from 1972 to 1974. During this period, he also served as head of the NCI-VA Cell Kinetics Laboratory, as NCI-VA Director of Medical Education, and as Executive Officer of the NCI Work Group for Therapy of Lung Cancer. At the National Cancer Institute he worked on cancer drug studies in mice which established optimal ways of combining different drugs to improve outcomes. During this time he had a number of studies published in cancer research journals. [5] [6]

In 1973 he was recruited as Chief of Oncology and Associate Professor of Medicine at Boston University Medical Center [4] where his clinical and research work focused primarily on breast and lung cancers. [7] [8] [9] While at BU, Straus was among the recipients of the Ten Outstanding Young Leaders Award from the Greater Boston Chamber of Commerce. [10]

After leaving BU in 1978, Straus took up posts at the Westchester County Medical Center where he continued his clinical and laboratory research work. From 1978 to 1982 he was Professor of Medicine and Chief of Neoplastic Diseases at the New York Medical College. [11]

Straus is the author of more than 40 peer-reviewed and published scientific papers pertaining to the treatment of cancer. [12] [13] [14]

He is a fellow of the American College of Physicians.

Healthcare business ventures

From 1982 to 2008, he headed Access Medical Group, a multi-specialty group in the Hudson Valley, New York, which had 36 doctors. In 1997 he founded a medical management company that managed 300 doctors in New York state.

In 1982, Straus started CarePlus, a publicly trade home nutrition company.[ citation needed ] In 1983 he founded Medical Registry Services, a software company pthat providescancer registry software support for hospitals. In 2008 he and his son, Ari, founded MDINR, a software company wthatsupported doctors treating patients with the anti-coagulant, Coumadin, also sold under the brand name Warfarin.[ citation needed ]

Straus was president of The Oxford Medical Group, P.C. and chief executive officer and chair of MDx Med-Care. [15]

Writing career

In 1991 Straus took a poetry workshop at the 92nd Street Y in New York City. He was later awarded a writing residency at Yaddo, an artists' community located on a 400-acre estate in Saratoga Springs, New York. [16] In 1999 Straus was awarded the Robert Penn Warren Award Lecture in the Humanities from Yale University Medical School. [15] [17]

Straus left his full-time medical practice in 2006 and began focusing on his poetry. By 2009 he had published more than 100 poems and three books. [1] His poems have been published in more than 100 journals including K the enyon Review, Ploughshares, and TriQuarterly.His work often deals with doctor patient communication. Many poems are in the voices of patients or doctors. [18]

Straus' work was the basis of a 2004 exhibition at Lehigh University called "THE BRIDGE: A Journey Through Illness" with a catalog and essay by poet John Yau. [19]

Contemporary art

Straus made his first art acquisition of four Milton Resnick paintings while still a teenager. [3]

Straus and his wife, Livia, began collecting contemporary art by 1966. Their collection has been featured in The NY Times, [20] [21] Forbes, Harper's Bazaar, Contemporanea, [22] Art & Antiques, and ARTnews. [23] The couples' personal art collection includes four pop art prints and one oil painting by Roy Lichtenstein, two works by Claes Oldenburgs (plaster loaves of bread from 1961 and a molded rubber screw from 1975), and three works by Jasper Johns. [20] Their collection has been listed in Art & Antiques as one of the Top 100 collections in the US. [24]

Straus has written some 35 articles in leading publications on art collecting and art criticism [25] [26] [27] and was president of the Aldrich museum of Contemporary Art in Ridgefield Connecticut. [28]

In 2002 the couple founded the Hudson Valley Center for Contemporary Art, turning a 12,000 sq ft former paneling factory in Peekskill NY into a space for cutting-edge contemporary art by artists like Folkert de Jong and Thomas Hirschhorn. [29] The facility was later renamed the Hudson Valley MOCA. Its focus is on emerging artists from around the world and supporting an economically challenged area with education programs. [30]

Straus opened MARC STRAUS, a contemporary art gallery on Grand Street, Manhattan, in 2011. NYC across the street from where his father's store had been. The gallery represents 24 artists from 16 different counties. In 2014 Flash Art listed MARC STRAUS as among the top 100 galleries in the world. [ citation needed ]

Philanthropic work

In 2001 Straus and his wife established the Marc and Livia Straus Foundation to support their artistic endeavors. [31]

Straus was a Trustee of Franklin and Marshall College from 1994 – 2004. [32] He also funded the establishment of the school’s first Jewish Studies program. [33]

In 2017, the Strauses donated the former Devitt’s Medical Arts Building in New Windsor, NY to Abilities First, a regional provider of education, vocational development, and residential for individuals with developmental disabilities. [34] The gift, valued at $3.2M, was the largest in the organization’s history. The building became the first Orange County location for the Abilities First School and was named in honor of Straus and his family. [35]

Personal life

Straus and his wife met while the two were teenagers. [3] They live in Chappaqua, NY. [36]

Allegations of research misconduct

In June 1978, two nurses and two trainees who worked with him at the Boston University School of Medicine (BUSM) alleged that Straus had ordered them to falsify patients' records, [37] had failed to get proper consent from patients, and had improperly administered drugs. [37] [38] Straus denied personal involvement in wrongdoing [11] [39] asserting his innocence [40] and maintaining that he had been framed by disgruntled subordinates. [41] [42]

Straus resigned from his posts at Boston University Medical Center Hospital (since 1996 part of Boston Medical Center) and BUSM. [43] [11] later that month. Following his resignation, Straus made multiple requests for external peer review of the charges against him. BU refused, leading Straus to conclude that the internal evaluation of his work was tainted because of investigator bias and lack of protection for the records. [44]

In 1980, while the investigation was ongoing, the National Cancer Institute awarded Straus a three-year grant of about $910,000 to conduct research. In 1981, Vincent T. DeVita Jr., Director of the NCI testified before Congress, saying that "his agencies award last year of a $910,000 research grant to a scientist last year... (Straus) …on the ground that ...the charges …had not yet been proven. [45]

One year later, Straus filed a $33 million lawsuit against five of his former co-workers, charging they had conspired to discredit his work. [46] Straus strongly denied that he had engaged in any wrongdoing alleging that his signature had been forged. [47]

Ruth Moran, MD, PhD, Straus’ lab chief from 1972 testified:

"Having worked side by side with Dr. Straus for 8 years ...the allegations to be totally inconsistent with what I know his scientific standards to be... The (BUMC) committee refused to see me. Dr. Straus’ chief data manager (Mary Jane Rimmer, R.N.) reported to me ... that she had always been instructed by Dr. Straus to record data accurately." [48]

"Scientists Supporting the Rights of Marc J. Straus, M.D." convened 78 cancer doctors and researchers in 1981, chaired by Mendel Krim, M.D. and Ruth Moran, MD Ph.D. They petitioned Vincent T. DeVita, Director NCI, and Arthur Hayes, Commissioner of the FDA, for a unitary blue ribbon review with full disclosure of relevant documents. [49]

After becoming convinced that this legal outcome was unavoidable, Straus settled with the U.S. Department of Health and Human Services in 1982, acknowledging that false reports were submitted without his knowledge. [39] [40] [41]

In October 1982, Straus published a paper in Cancer Treatment Reports , a journal funded by the National Cancer Institute. The propriety of that publication was questioned in the journal Science . [42] Straus continued to publish scientific clinical studies through 1998. [50]

Books

LUNG CANCER Clinical Diagnosis and Treatment (1977) Edited by Marc J. Straus, M.D. Grune & Stratton [51]

LUNG CANCER Clinical Diagnosis and Treatment (1983) Edited by Marc J. Straus, M.D. Grune & Stratton [51]

SCARLET CROWN (1994), Aureole Press, Craftsman Printers [52]

ONE WORD (1994), TriQuarterly Books, Northwestern University Press [53]

SYMMETRY (2000), TriQuarterly Books, Northwestern University Press [54]

NOT GOD: A Play in Verse (2006), TriQuarterly Books, Northwestern University Press. [18]

Select medical research [12]

Related Research Articles

<span class="mw-page-title-main">Leukemia</span> Blood cancers forming in the bone marrow

Leukemia is a group of blood cancers that usually begin in the bone marrow and produce high numbers of abnormal blood cells. These blood cells are not fully developed and are called blasts or leukemia cells. Symptoms may include bleeding and bruising, bone pain, fatigue, fever, and an increased risk of infections. These symptoms occur due to a lack of normal blood cells. Diagnosis is typically made by blood tests or bone marrow biopsy.

<span class="mw-page-title-main">Cytarabine</span> Chemical compound (chemotherapy medication)

Cytarabine, also known as cytosine arabinoside (ara-C), is a chemotherapy medication used to treat acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), chronic myelogenous leukemia (CML), and non-Hodgkin's lymphoma. It is given by injection into a vein, under the skin, or into the cerebrospinal fluid. There is a liposomal formulation for which there is tentative evidence of better outcomes in lymphoma involving the meninges.

<span class="mw-page-title-main">Vincristine</span> Chemical compound; chemotherapy medication

Vincristine, also known as leurocristine and marketed under the brand name Oncovin among others, is a chemotherapy medication used to treat a number of types of cancer. This includes acute lymphocytic leukemia, acute myeloid leukemia, Hodgkin's disease, neuroblastoma, and small cell lung cancer among others. It is given intravenously.

<span class="mw-page-title-main">Vincent T. DeVita</span> American oncologist and academic

Vincent Theodore DeVita Jr. is the Amy and Joseph Perella Professor of Medicine at Yale Cancer Center, and a Professor of Epidemiology and Public Health. He directed the Yale Cancer Center from 1993 to 2003. He has been president of the board of directors of the American Cancer Society (2012-2013). He is internationally recognized as a pioneer in the field of oncology for his work on combination-chemotherapy treatments.

<span class="mw-page-title-main">History of cancer chemotherapy</span>

The era of cancer chemotherapy began in the 1940s with the first use of nitrogen mustards and folic acid antagonist drugs. The targeted therapy revolution has arrived, but many of the principles and limitations of chemotherapy discovered by the early researchers still apply.

<span class="mw-page-title-main">Vinorelbine</span> Pharmaceutical drug

Vinorelbine (NVB), sold under the brand name Navelbine among others, is a chemotherapy medication used to treat a number of types of cancer. This includes breast cancer and non-small cell lung cancer. It is given by injection into a vein or by mouth.

<span class="mw-page-title-main">Targeted therapy</span> Type of therapy

Targeted therapy or molecularly targeted therapy is one of the major modalities of medical treatment (pharmacotherapy) for cancer, others being hormonal therapy and cytotoxic chemotherapy. As a form of molecular medicine, targeted therapy blocks the growth of cancer cells by interfering with specific targeted molecules needed for carcinogenesis and tumor growth, rather than by simply interfering with all rapidly dividing cells. Because most agents for targeted therapy are biopharmaceuticals, the term biologic therapy is sometimes synonymous with targeted therapy when used in the context of cancer therapy. However, the modalities can be combined; antibody-drug conjugates combine biologic and cytotoxic mechanisms into one targeted therapy.

<span class="mw-page-title-main">Non-small-cell lung cancer</span> Any type of epithelial lung cancer other than small-cell lung carcinoma

Non-small-cell lung cancer (NSCLC), or non-small-cell lung carcinoma, is any type of epithelial lung cancer other than small-cell lung cancer (SCLC). NSCLC accounts for about 85% of all lung cancers. As a class, NSCLCs are relatively insensitive to chemotherapy, compared to small-cell carcinoma. When possible, they are primarily treated by surgical resection with curative intent, although chemotherapy has been used increasingly both preoperatively and postoperatively.

<span class="mw-page-title-main">Cancer and Leukemia Group B</span> U.S. research cooperative group

Cancer and Leukemia Group B is a cancer research cooperative group in the United States.

Emil J. Freireich was an American hematologist, oncologist, and cancer biologist. He was recognized as a pioneer in the treatment of cancer and use of chemotherapy and is often known as the father of modern leukemia therapy.

Nicholas James Gonzalez was a New York–based physician known for developing the Gonzalez regimen, an alternative cancer treatment. Gonzalez's treatments are based on the belief that pancreatic enzymes are the body's main defense against cancer and can be used as a cancer treatment. His methods have been generally rejected by the medical community. and he has been characterized as a quack and fraud by other doctors and health fraud watchdog groups. In 1994 Gonzalez was reprimanded and placed on two years' probation by the New York State Medical Board for "departing from accepted practice".

<span class="mw-page-title-main">Cancer treatment</span> Overview of various treatment possibilities for cancer

Cancer treatments are a wide range of treatments available for the many different types of cancer, with each cancer type needing its own specific treatment. Treatments can include surgery, chemotherapy, radiation therapy, hormonal therapy, targeted therapy including small-molecule drugs or monoclonal antibodies, and PARP inhibitors such as olaparib. Other therapies include hyperthermia, immunotherapy, photodynamic therapy, and stem-cell therapy. Most commonly cancer treatment involves a series of separate therapies such as chemotherapy before surgery. Angiogenesis inhibitors are sometimes used to enhance the effects of immunotherapies.

VAMP regimen or VAMP chemotherapy is a four-drug combination chemotherapy regimen, used today in the treatment of Hodgkin lymphoma. It was one of the earliest combination chemotherapy regimens, originally developed as a treatment for childhood leukemia by a group of researchers at the National Cancer Institute led by Emil Frei and Emil Freireich. The first clinical trial of VAMP began in 1961. Because it was the first time that four chemotherapeutic agents were used at once, the trial was highly controversial at its time. Although new combination chemotherapy regimens have replaced the use of VAMP in the treatment of childhood leukemia, VAMP is considered an important precursor to modern treatments, confirming the effectiveness of combination chemotherapy and leading to the use of combination chemotherapy regimens to treat other types of cancer.

The Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine is a cancer treatment, research and education institution with six locations in the St. Louis area. Siteman is the only cancer center in Missouri and within 240 miles of St. Louis to be designated a Comprehensive Cancer Center by the National Cancer Institute (NCI). Siteman is also the only area member of the National Comprehensive Cancer Network, a nonprofit alliance of 32 cancer centers dedicated to improving the quality and effectiveness of cancer care.

High-dose chemotherapy and bone marrow transplant (HDC/BMT), also high-dose chemotherapy with autologous bone marrow transplant, was an ineffective treatment regimen for metastatic breast cancer, and later high-risk breast cancer, that was considered promising during the 1980s and 1990s. With an overall idea that more is better, this process involved taking cells from the person's bone marrow to store in a lab, then to give such high doses of chemotherapy drugs that the remaining bone marrow was destroyed, and then to inject the cells taken earlier back into the body as replacement. It was ultimately determined to be no more effective than normal treatment, and to have significantly higher side effects, including treatment-related death.

<span class="mw-page-title-main">Min Chiu Li</span> American physician

Min Chiu Li was a Chinese-American oncologist and cancer researcher. Li was the first scientist to use chemotherapy to cure widely metastatic, malignant cancer.

Waun Ki Hong was Professor of Medicine at The University of Texas MD Anderson Cancer Center, where he served as chairman of the Department of Thoracic/Head & Neck Medical Oncology from 1993 to 2005 and as head of the Division of Cancer Medicine from 2001 to 2014. He was also an American Cancer Society Professor and the Samsung Distinguished University Chair in Cancer Medicine emeritus.

<span class="mw-page-title-main">James F. Holland</span> American physician (1925–2018)

James Frederick Holland was an American physician and Distinguished Professor of Neoplastic Diseases at the Icahn School of Medicine at Mount Sinai in New York. Early in his career, he had worked for the National Cancer Institute and Roswell Park Comprehensive Cancer Center.

<span class="mw-page-title-main">Bisantrene</span> Chemical compound

Bisantrene is an anthracenyl bishydrazone with anthracycline-like antineoplastic activity and an antimetabolite. Bisantrene intercalates with and disrupts the configuration of DNA, resulting in DNA single-strand breaks, DNA-protein crosslinking, and inhibition of DNA replication. This agent is similar to doxorubicin in chemotherapeutic activity, but unlike anthracyclines like doxorubicin, it exhibits little cardiotoxicity.

Dorris Hutchison was an American scientist primarily known for her studies on the development of cancer chemotherapy drugs. Her work has been crucial for the advancement of new treatments for leukemia.

References

  1. 1 2 3 Frey, Jennifer (April 9, 2009). "Poet-Playwright (and M.D.) Examines Doctor-Patient Link". The New York Times. ISSN   0362-4331 . Retrieved July 28, 2021.
  2. ↑ Moran, Ruth E.; Straus, Marc J. (December 1, 1981). "Effects of Pulse and Continuous Intravenous Infusion of cis-Diamminedichloroplatinum on L1210 Leukemia in Vivo". Cancer Research. 41 (12 Part 1): 4993–4996. PMID   7198009.
  3. 1 2 3 "THE STRAUS COLLECTION » FLATT". FLATT. Retrieved July 28, 2021.
  4. 1 2 3 Oversight, United States Congress House Committee on Science and Technology Subcommittee on Investigations and (1981). Fraud in Biomedical Research: Hearings Before the Subcommittee on Investigations and Oversight of the Committee on Science and Technology, U.S. House of Representatives, Ninety-seventh Congress, First Session, March 31, April 1, 1981. U.S. Government Printing Office.
  5. ↑ Straus MJ, Mantel N, Goldin A (1971). "Effects of priming dose schedules in methotrexate treatment of mouse leukemia L1210". Cancer Research. 31 (10): 1429–33. PMID   5095131.
  6. ↑ Straus MJ, Straus SE, Krezoski S, Battiste L (1977). "The uptake, excretion, and radiation hazards of tritiated thymidine in humans". Cancer Research. 37 (2): 610–8. PMID   832281.
  7. ↑ Straus MJ, Moran RE (1977). "Cell cycle parameters in human solid tumors". Cancer. 40 (4): 1453–61. doi: 10.1002/1097-0142(197710)40:4<1453::AID-CNCR2820400416>3.0.CO;2-E . PMID   907963. S2CID   10466852.
  8. ↑ Straus MJ (1979). "New developments in the treatment of advanced lung cancer". The American Review of Respiratory Disease. 120 (5): 967–71. doi:10.1164/arrd.1979.120.5.967 (inactive November 1, 2024). PMID   228574.{{cite journal}}: CS1 maint: DOI inactive as of November 2024 (link)
  9. ↑ Straus MJ, Moran RE (1980). "The cell cycle kinetics of human breast cancer". Cancer. 46 (12): 2634–9. doi:10.1002/1097-0142(19801215)46:12<2634::aid-cncr2820461217>3.0.co;2-k. PMID   7448702. S2CID   20536307.
  10. ↑ City Awake a program of the Greater Boston Chamber of Commerce. "Ten Outstanding Young Leaders" (PDF). City Awake.
  11. 1 2 3 "Doctor Admits Filing False Data and Is Barred from U.S. Support". New York Times . May 20, 1982. Retrieved August 20, 2016.
  12. 1 2 "Google Scholar". scholar.google.com. Retrieved July 28, 2021.
  13. ↑ Straus MJ, Choi SC (1973). "Association of increased height with renovascular hypertension". JAMA. 223 (4): 440–1. doi:10.1001/jama.1973.03220040054022. PMID   4739127.
  14. ↑ Straus MJ (1976). "Combination chemotherapy in advanced lung cancer with increased survival". Cancer. 38 (6): 2232–41. doi: 10.1002/1097-0142(197612)38:6<2232::aid-cncr2820380607>3.0.co;2-k . PMID   187314. S2CID   39490372.
  15. 1 2 "Attorney for Terry Nichols, Greek Orthodox Archbishop, Inventor, Safari Guide and others to Speak at Yale". YaleNews. March 20, 1998. Retrieved July 30, 2021.
  16. ↑ "Writers – Yaddo". www.yaddo.org. Retrieved July 28, 2021.
  17. ↑ "Yale Bulletin and Calendar – Visiting on Campus". archives.news.yale.edu. Retrieved July 30, 2021.
  18. 1 2 Straus, Marc J. (May 15, 2006). Not God: A Play in Verse. Northwestern University Press. ISBN   978-0-8101-5169-7.
  19. ↑ Yau, John (2004). The Bridge: A Journey Through Illness: Rick Levinson, Visual Artist: Marc J. Straus, Poet: April 7 – June 20, 2004. Lehigh University Art Galleries/Museum Operation.
  20. 1 2 Zimmer, William (August 20, 1989). "ART; A Private and Passionate Taste for the Contemporary". The New York Times. ISSN   0362-4331 . Retrieved July 30, 2021.
  21. ↑ Russell, John: Contemporary Classics at Aldrich. The New York Times, August 4, 1989, C23.
  22. ↑ Facts and Fancy: A Review of The Whitney Biennial. Contemporanea. 2: 6-7/89, 87–89.
  23. ↑ Pollack, Barbara: The Straus Collection. ArtNews, November 1999, p. 144-146.
  24. ↑ Pacheco, Patrick: America's Top 100 Collectors. Art & Antiques, March 1995, p. 106.
  25. ↑ Who's On First. Review of Whitney Biennial. Provincetown Arts. Summer, 1997.
  26. ↑ In the Lineage of Eva Hesse. for catalog – In the Lineage of Eva Hesse: Aldrich Museum of Contemporary Art. January- May 1994.
  27. ↑ THE ART MARKET: Flash Art November 2010.
  28. ↑ "The Authenticity Scout: Dealer Kerry Schuss on Discovering Artistic Geniuses of All Ages (Where You Least Expect It)". Artspace. Retrieved July 30, 2021.
  29. ↑ "Your Complete Guide to Westchester's Artistic Venues". Westchester Magazine. March 26, 2021. Retrieved July 28, 2021.
  30. ↑ "22 Things Every Westchester Resident Needs to Do". Westchester Magazine. February 27, 2019. Retrieved July 28, 2021.
  31. ↑ "THE MARC & LIVIA STRAUS FOUNDATION, INC. | New York Company Directory". www.nycompanyregistry.com. Retrieved July 28, 2021.
  32. ↑ "F&M's Westchester/Southern Connecticut Regional Chapter Presents "After the Fall" – An Exclusive Viewing of Eastern European Art with Marc Straus '65" (PDF). F&M Event Catalog for Blue Chapters: 27–28. November 2010.
  33. ↑ "From Exclusion to Celebration". www.fandm.edu. Retrieved July 28, 2021.
  34. ↑ Dunne, Allison (July 2, 2017). "Donation Enables Abilities First School For Orange County". www.wamc.org. Retrieved July 28, 2021.
  35. ↑ Axelrod, Daniel. "Abilities First to get permanent OC home". recordonline.com. Retrieved July 28, 2021.
  36. ↑ "Museum Quality". Upstate House. June 1, 2016. Retrieved July 28, 2021.
  37. 1 2 Charrow, Robert P. (July 15, 2010). Law in the Laboratory: A Guide to the Ethics of Federally Funded Science Research. University of Chicago Press. pp. 52–53, 104. ISBN   978-0226101651 . Retrieved August 20, 2016.
  38. ↑ "Cancer Institute 'fines' accused scientist". New Scientist : 420. February 18, 1982. Retrieved August 20, 2016.
  39. 1 2 "Dr. Marc J. Straus, a cancer researcher barred from…". UPI . May 21, 1982. Retrieved August 22, 2016.
  40. 1 2 "Doctor Denies Role in Fraud". New York Times . May 21, 2016. Retrieved August 20, 2016.
  41. 1 2 Hilts, Philip J. (May 20, 1982). "Cancer Researcher Punished in Fraud Case". Washington Post . Retrieved August 20, 2016.
  42. 1 2 Sun, M. (January 21, 1983). "Banned researcher publishes a paper". Science . 219 (4582): 270. Bibcode:1983Sci...219..270S. doi:10.1126/science.11644000. PMID   11644000.
  43. ↑ "Cancer research validity is criticized". The Day . July 17, 1980. Retrieved August 20, 2016.
  44. ↑ Judith P. Swazey and Stephen R. Scher (September 21–22, 1981). "Policies and Procedures for Responding to Reports of Misconduct". President's Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research: 76–77.
  45. ↑ Times, Robert Reinhold, Special To The New York (June 3, 1981). "HEAD OF CANCER AGENCY DEFENDS AWARD OF GRANT TO ACCUSED SCIENTIST". The New York Times. ISSN   0362-4331 . Retrieved September 13, 2016.{{cite news}}: CS1 maint: multiple names: authors list (link)
  46. ↑ Ap (June 6, 1981). "Researcher Sues 5 For Conspiracy". The New York Times. ISSN   0362-4331 . Retrieved September 13, 2016.
  47. ↑ Broad, W. J. (June 19, 1981). "Straus defends himself in Boston". Science. 212 (4501): 1367–1369. Bibcode:1981Sci...212.1367B. doi:10.1126/science.7015514. ISSN   0036-8075. PMID   7015514.
  48. ↑ "A Guide to the Archival Collection of The President's Commission for the Study of Ethical Problems in Medicine and in Biomedical and Behavioral Research" (PDF).
  49. ↑ "Dr. Marc J. Straus, a cancer researcher barred from…" . Retrieved September 13, 2016.
  50. ↑ Moran RE, Black MM, Alpert L, Straus MJ (1984). "Correlation of cell-cycle kinetics, hormone receptors, histopathology, and nodal status in human breast cancer". Cancer. 54 (8): 1586–90. doi:10.1002/1097-0142(19841015)54:8<1586::aid-cncr2820540820>3.0.co;2-9. PMID   6478400. S2CID   23348035.
  51. 1 2 Straus, Marc J. (1983). Lung Cancer: Clinical Diagnosis and Treatment. Grune & Stratton. ISBN   978-0-8089-1487-7.
  52. ↑ Straus, Marc (1994). Scarlet Crown. Aureole Press.
  53. ↑ Straus, Marc J. (October 26, 1994). One Word. Northwestern University Press. ISBN   978-0-8101-5035-5.
  54. ↑ Straus, Marc J. (2000). Symmetry. Northwestern University Press. ISBN   978-0-8101-5096-6.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.